Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
We developed a multilayered mixed-cell sheet consisting of fibroblasts and peripheral blood mononuclear cells as a treatment for refractory cutaneous ulcers. The concentration of secreted VEGF, HGF, TGF-β1, CXCL-1, CXCL-2 in multilayered mixed-cell sheets was much higher than that in single-layered mixed-cell sheets. The supernatant in multilayered sheets enhanced angiogenic potency and fibroblast migration compared with single-layered mixed-cell sheets in an in vitro experiment. The wound healing rate in the multilayered mixed-cell sheet-treated group was higher compared with the no-treatment group (control) at the early stage of healing. Moreover, both vessel lumen area and microvessel density in tissues treated with multilayered sheets were significantly increased compared with tissues in the control group. These data suggest that multilayered sheets may be a promising therapeutic material for refractory cutaneous ulcers.
|